

Supplementary Table S1. Anti-Jo1 cohort Characteristics according to anti-Ro52 antibodies status.

	Anti-Ro52 positive	Anti-Ro52 negative	<i>p</i>
Number (%)	29 (58)	21 (42)	-
Female gender (%)	23 (79)	9 (43)	0.008
Male gender (%)	6 (21)	12 (57)	
Median age in years at disease onset (IQR)	6 (2-15)	12 (2-48)	0.764
Median diagnostic delay in months (IQR)	5 (2-15)	10.5 (3-48)	0.577
Median follow-up in months (IQR)	64 (51-99)	62 (36-104)	0.817
Arthritis at disease onset (%)	21 (72)	18 (86)	0.262
Arthritis at last follow-up (%)	26 (90)	17 (81)	0.381
Myositis at disease onset (%)	12 (41)	13 (62)	0.151
Myositis at last follow-up (%)	17 (59)	19 (90)	0.013
Classic onset (%)	10 (34)	14 (67)	0.482
Hypomyopathic onset (%)	7 (24)	5 (24)	
ILD ¥ at disease onset (%)	15 (52)	10 (48)	0.774
ILD at last follow-up (%)	29 (100)	19 (90)	0.171
Acute onset (%)	10 (34)	4 (19)	0.354
Chronic onset (%)	13 (45)	9 (43)	
Asymptomatic onset (%)	6 (21)	6 (29)	
Complete ASSD II at disease onset (%)	8 (28)	4 (19)	0.526
Incomplete ASSD at disease onset (%)	21 (72)	17 (81)	
Incomplete ASSD at disease onset with <i>de-novo</i> triad findings (%)	15 (52)	11 (52)	1
Complete ASSD at last follow-up(%)	15 (52)	14 (67)	0.387
Incomplete ASSD at last follow-up (%)	14 (48)	7 (33)	
Raynaud's phenomenon (%)	8 (28)	7 (33)	0.758
Mechanic's hands (%)	10 (34)	10 (48)	0.392
Fever (%)	8 (28)	5 (24)	1

*Rheumatoid arthritis; ¥Interstitial lung disease; llantisynthetase syndrome.

Supplementary Table S2. Non-anti-Jo1 cohort characteristics according to anti-Ro52 antibodies status.

	Anti-Ro52 positive	Anti-Ro52 negative	<i>p</i>
Number (%)	5 (50)	5 (50)	-
Female gender (%)	5 (100)	2 (40)	0.166
Male gender (%)	0 (0)	3 (60)	
Median age in years at disease onset (IQR)	54 (51-58)	52 (50-78)	0.543
Median diagnostic delay in months (IQR)	5 (4-5)	7 (7-52)	0.059
Median follow-up in months (IQR)	45 (40-50)	47 (25-50)	0.931
Arthritis at disease onset (%)	3 (60)	2 (40)	1
Arthritis at last follow-up (%)	3 (60)	2 (40)	1
Myositis at disease onset (%)	1 (20)	2 (40)	1
Myositis at last follow-up (%)	3 (60)	3 (60)	1
Classic onset (%)	5 (100)	3 (60)	0.44
Hypomyopathic onset (%)	0 (100)	2 (40)	
ILD ¥ at disease onset (%)	2 (40)	2 (40)	1
ILD at last follow-up (%)	5 (100)	2 (40)	0.166
Acute onset (%)	0 (0)	0 (0)	0.44
Chronic onset (%)	3 (60)	5 (100)	
Asymptomatic onset (%)	2 (40)	0 (0)	
Complete ASSD II at disease onset (%)	0 (0)	0 (0)	1
Incomplete ASSD at disease onset (%)	5 (100)	5 (100)	
Incomplete ASSD at disease onset with <i>de-novo</i> triad findings (%)	3 (60)	1 (20)	0.52
Complete ASSD at last follow-up(%)	2 (40)	0 (0)	0.44
Incomplete ASSD at last follow-up (%)	3 (60)	5 (100)	
Raynaud's phenomenon (%)	0 (0)	1 (20)	1
Mechanic's hands (%)	2 (40)	3 (60)	1
Fever (%)	4 (80)	0 (0)	0.047

*Rheumatoid arthritis; ¥Interstitial lung disease; llantisynthetase syndrome.